Dual-drug-loaded MSCs-derived exosomal vesicles inhibit endometrial cancer cell proliferation by promoting apoptosis through the migration and invasion of Rac1/NF-κB/MMP2 signalling pathway

IF 2.5 4区 生物学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
{"title":"Dual-drug-loaded MSCs-derived exosomal vesicles inhibit endometrial cancer cell proliferation by promoting apoptosis through the migration and invasion of Rac1/NF-κB/MMP2 signalling pathway","authors":"","doi":"10.1007/s12257-024-00088-4","DOIUrl":null,"url":null,"abstract":"<span> <h3>Abstract</h3> <p>Endometrial carcinoma affects the uterine lining. Endogenous activity, intrinsic targeting, and ability to engage with a host defence system make exosomal vehicles (EVs) a viable cancer treatment alternative. Due to these benefits, mesenchymal stem cell (MSC)-derived EVs loaded with carboplatin and paclitaxel could resemble immune cells to fight cancer. This study found that Car-Pac@EVs downregulated endometrial cancer (EC) cells relative to normal endometrium. Car-Pac@EVs' effects on ECC-1 and HEC-1A EC cells at different doses were examined in vitro. To detect cancer, MTT, flow cytometry, and transwell assays were used. Protein expression was measured by Western blotting and qRT-PCR. Car-Pac@EVs were affected by time- and dose-dependent EC cell proliferation reductions. In EC cells, Car-Pac@EVs triggered apoptosis. Car-Pac@EVs formulation reduced EC cell migration and invasion by reducing MMP-2 expression via Rac1/NF-κB signalling. The results indicated that Car-Pac@EVs may be an effective EC diagnosis and treatment target.</p> </span> <span> <h3>Graphical abstract</h3> <p><span> <span> <img alt=\"\" src=\"https://static-content.springer.com/image/MediaObjects/12257_2024_88_Figa_HTML.png\"/> </span> </span></p> </span>","PeriodicalId":8936,"journal":{"name":"Biotechnology and Bioprocess Engineering","volume":"56 1","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnology and Bioprocess Engineering","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1007/s12257-024-00088-4","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Endometrial carcinoma affects the uterine lining. Endogenous activity, intrinsic targeting, and ability to engage with a host defence system make exosomal vehicles (EVs) a viable cancer treatment alternative. Due to these benefits, mesenchymal stem cell (MSC)-derived EVs loaded with carboplatin and paclitaxel could resemble immune cells to fight cancer. This study found that Car-Pac@EVs downregulated endometrial cancer (EC) cells relative to normal endometrium. Car-Pac@EVs' effects on ECC-1 and HEC-1A EC cells at different doses were examined in vitro. To detect cancer, MTT, flow cytometry, and transwell assays were used. Protein expression was measured by Western blotting and qRT-PCR. Car-Pac@EVs were affected by time- and dose-dependent EC cell proliferation reductions. In EC cells, Car-Pac@EVs triggered apoptosis. Car-Pac@EVs formulation reduced EC cell migration and invasion by reducing MMP-2 expression via Rac1/NF-κB signalling. The results indicated that Car-Pac@EVs may be an effective EC diagnosis and treatment target.

Graphical abstract

Abstract Image

通过Rac1/NF-κB/MMP2信号通路的迁移和侵袭促进凋亡,从而抑制子宫内膜癌细胞增殖
摘要 子宫内膜癌会影响子宫内膜。外泌体载体(EVs)具有内源性活性、内在靶向性和与宿主防御系统结合的能力,因此是一种可行的癌症治疗选择。由于这些优点,间充质干细胞(MSC)衍生的载入卡铂和紫杉醇的外泌体可类似于免疫细胞来对抗癌症。这项研究发现,相对于正常子宫内膜,Car-Pac@EVs可下调子宫内膜癌(EC)细胞。研究人员在体外检测了不同剂量的Car-Pac@EVs对ECC-1和HEC-1A EC细胞的影响。为了检测癌细胞,使用了 MTT、流式细胞术和透孔试验。蛋白表达通过 Western 印迹和 qRT-PCR 检测。Car-Pac@EV对EC细胞增殖的降低具有时间和剂量依赖性。在 EC 细胞中,Car-Pac@EVs 会引发细胞凋亡。Car-Pac@EVs制剂通过Rac1/NF-κB信号减少了MMP-2的表达,从而降低了EC细胞的迁移和侵袭。结果表明,Car-Pac@EVs可能是一种有效的心血管疾病诊断和治疗靶标。 图表摘要
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Biotechnology and Bioprocess Engineering
Biotechnology and Bioprocess Engineering 工程技术-生物工程与应用微生物
CiteScore
5.00
自引率
12.50%
发文量
79
审稿时长
3 months
期刊介绍: Biotechnology and Bioprocess Engineering is an international bimonthly journal published by the Korean Society for Biotechnology and Bioengineering. BBE is devoted to the advancement in science and technology in the wide area of biotechnology, bioengineering, and (bio)medical engineering. This includes but is not limited to applied molecular and cell biology, engineered biocatalysis and biotransformation, metabolic engineering and systems biology, bioseparation and bioprocess engineering, cell culture technology, environmental and food biotechnology, pharmaceutics and biopharmaceutics, biomaterials engineering, nanobiotechnology, and biosensor and bioelectronics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信